Fairtility is transforming in vitro fertilization (IVF) with AI technology that improves clinical outcomes and reduces the number of cycles needed for a live birth, lessening the emotional, physical, and financial burden on patients while fostering collaboration between clinicians and parents.
Its transparent AI platform, CHLOE (Cultivating Human Life through Optimal Embryos), provides full visibility into clinical and laboratory parameters across the IVF process. Starting with CHLOE EQ, a proprietary embryo grading tool, Fairtility is expanding its platform to support infertility assessment, oocyte and embryo evaluation, clinical decision-making, and transfer optimization, enhancing consistency, efficiency, and patient experience.
